Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Original Article

Quality of evidence supporting Surviving Sepsis Campaign Recommendations

Jordi Rello a,b,c,1, Sofia Tejada a,b,*,1, Elena Xu d, Candela Solé-Lleona, Laura Campogiani f, Despoina Koulenti d,g, João Ferreira-Coimbra h, Jeff Lipman c,d

a Clinical Research/Epidemiology in Pneumonia & Sepsis (CRIPS), Vall d’Hebron Institut of Research (VHIR), Barcelona, Spain
b Centro de Investigacion Biomédica En Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain
c Scientific Research, CHU Nîmes, University Montpellier-Nîmes, Nîmes, France
d UQ Centre for Clinical Research, Faculty of Medicine, University of Queensland, Brisbane, Australia
e Intensive Care Unit, Hospital Universitari de Vic, Barcelona, Spain
f Centro Infecciosas, Hospital Universitario, Salamanca, Spain
h Clinical Infectious Diseases, Department of System Medicine, Tor Vergata University, Rome, Italy
i Department of Critical Care II, Attikon University Hospital, Athens, Greece
j Internal Medicine Department, Centro Hospitalar Universitário do Porto, Porto, Portugal

A R T I C L E   I N F O

Article history:
Available online xxx

Keywords:
Antimicrobial administration
Haemodynamic resuscitation
Mechanical ventilation
Clinical practice guidelines
Septic shock

A B S T R A C T

Introduction: The Surviving Sepsis Campaign (SSC) guidelines, released in 2017, are a combination of expert opinion and evidence-based medicine, adopted by many institutions as a standard of practice. The aim was to analyse the quality of evidence supporting recommendations on the management of sepsis.

Methods: The strength and quality of evidence (high, moderate, low-very low and best practice statements) of each recommendation were extracted. Randomised controlled trials were required to qualify as high-quality evidence.

Results: A total of 96 recommendations were formulated, and 87 were included. Among thirty-one (43%) strong recommendations, only 15.2% were supported by high-quality evidence. Overall, thirty-seven (42.5%) recommendations were based on low-quality evidence, followed by 28 (32.2%) based on moderate-quality, 15 (17.2%) were best practice statements and only seven (8.0%) were supported by high-quality evidence. Randomised controlled trials supported 21.4%, 9.5% and 8.6% recommendations on mechanical ventilation, resuscitation, and management/adjuvant therapy, respectively. In contrast, none high-quality evidence recommendation supported antimicrobial/source control (82.4% were low very low evidence or best practice statements), and nutrition.

Conclusions: In the SSC guidelines most recommendations were informed by indirect evidence and non-systematic observations. While awaiting trials results, Delphi-like approaches or multi-criteria decision analyses should guide recommendations.

© 2020 Société française d’anesthésie et de réanimation (Sfar). Published by Elsevier Masson SAS. All rights reserved.

1. Introduction

Sepsis is a multi-factorial, life-threatening syndrome that arises from the body’s response to infection, leading to organ dysfunction [1]. Sepsis and septic shock, the severe forms of sepsis, are medical emergencies. The World Health Organization (WHO) estimates 30.7 million sepsis cases annually, with at least six million deaths [2]. In 2016, the WHO classified sepsis as a global health priority and have urged for the implementation of measures to improve prevention, diagnosis and management of sepsis [2].
Multiple clinical practice guidelines (CPG) have been developed to guide clinician care and management for patients with sepsis and septic shock. The first set of guidelines published by the Surviving Sepsis Campaign (SCC) were published in 2004 and revised in 2008 and 2012. The current guidelines [3] were published in 2017 and are based on updated research evidence. The quality of the evidence supporting each recommendation was assessed using the Grades of Recommendation, Assessment, Development, and Evaluation (GRADE) system [4], which takes into consideration the risk of bias, inconsistency, indirectness, imprecision and publication bias. This contributed to the formulation of either a strong or weak recommendation after weighing up the risks and benefits, patient preferences, cost, feasibility and practicality of the intervention. Recent research has found a majority of recommendations in CPGs in other medical fields, such as hospital-acquired pneumonia and ventilator-associated pneumonia [5], to be supported by low-quality evidence, with only a small number based on high-quality randomised controlled trials (RCT). As CPGs are used to guide patient care and management, it is imperative that these recommendations are based on high-quality evidence, namely well-conducted RCTs.

The main objective of this study is to evaluate the quality of evidence supporting the recommendations from the 2016 Surviving Sepsis Campaign and inform the relevant stakeholders of areas requiring further research in order to provide stronger evidence for the future updates. This is part of a broader research project of quality of evidence evaluation from different CPGs in respiratory and critical care medicine [5–7]. Recognising guidelines as an important tool to complement clinical reasoning and improve patient care, the aim of this project is to call attention to the weaknesses and to contribute to their future refinement.

2. Methods

The SSC guidelines [3] were identified and downloaded from PubMed. The recommendations for each guideline were abstracted by a single reviewer (EX) and supervised by one of the authors (ST). Questions formulated without reporting specific recommendations, or regarding screening, diagnosis and goals of care were excluded. A flow chart selection following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses [8] (PRISMA) guidelines was conducted.

The reviewers then recorded the level of evidence (LOE) [9] and strength of each recommendation. The LOE was clearly classified as high, moderate, low-very low quality, as determined by the guideline development team, so guideline content was not required to be reviewed. This was translated into LOE A (high; RCTs), LOE B (moderate; downgraded RCTs or upgraded observational studies) and LOE C (low-very low; observational studies, expert opinion or other evidence). Several best practice statements (BPS) are also included, representing ungraded recommendations in which the evidence was considered to be unequivocal, although difficult to assess using the GRADE method.

The strength of recommendation was determined by the phrasing: “We recommend”, was interpreted as a strong recommendation, and “We suggest”, as a weak recommendation. A strong recommendation implied that most individuals would want the recommended intervention and should be recommended by clinicians, whereas recommendations where many individuals would not want the intervention were classified as weak.

The recommendations were classified into five categories: resuscitation, antimicrobial and source control, management and adjuvant therapy, mechanical ventilation and nutrition. This choice was made in order to provide consistency in the various areas addressed. Resuscitation included recommendations regarding indications for initial resuscitation, fluid therapy, indications for vasoactive medications, and haemodynamic assessment. The category of antimicrobial and source control includes identifying the source of the infection, indications and contraindications for antibiotic therapy and administration and recommendations for monitoring with procalcitonin. Recommendations for corticosteroids, blood products, immunoglobulin, antiocoagulants and glucose were categorised under management and adjuvant therapies. Recommendations for mechanical ventilation and nutrition were classified in separate categories. Ethics approval was not applicable for this study.

3. Results

A total of 96 recommendations, including different sections of the same recommendation, were extracted from the 2016 SSC guidelines and after exclusions, 87 were analysed in this report. Fig. 1 reports a flow chart selection following the PRISMA guidelines. Distribution of level of evidence of recommendations is detailed in Table 1. The majority of recommendations were
based on low-quality evidence (37 [42.5%]), followed by 28 (32.2%) based on moderate-quality, 15 (17.2%) were BPSs and only seven (8.0%) supported by high-quality evidence (detailed in Table 2). Despite this, more than half were reported as strong recommendations (31 [43%]). Fig. 2 details levels of evidence depending on whether recommendations were formulated as weak or strong.

3.1. Resuscitation

From a total of 21 abstracted recommendations regarding resuscitation, almost half (6 [35.3%]) were characterised as strong. However, only 2 of these (9.5%) were based on high-quality evidence (Table 1). These recommendations (Table 2) were “against” hydroxyethyl starches and low-dose dopamine use.

3.2. Antimicrobial and source control

Although 10 out of a total of 17 abstracted recommendations involving antimicrobial and source control were characterised as strong, none qualified as high quality due to the lack of RCT supporting them (Tables 1 and 2).

3.3. Mechanical ventilation

Fourteen recommendations for mechanical ventilation were abstracted, 10 of which were characterised as strong recommendations (Table 1). A protective ventilator strategy and using spontaneous breathing trials for weaning were high-quality recommendations, as well as a negative recommendation of monitoring sepsis-induced acute respiratory distress syndrome (ARDS) with pulmonary artery catheterisation (Table 2).

3.4. Nutrition

A total of 12 recommendations were abstracted for nutrition, categorised into 5 (41.7%) strong and 7 (58.3%) weak recommendations. Of the 5 strong recommendations, none was based on high-quality evidence (Tables 1 and 2).

3.5. Management and adjuvant therapy

Recommendations regarding management, specific measures and adjuvant therapies in critically ill patients comprised the largest group (26.4%) of SSC recommendations. Among 23 recommendations, almost half (11 [47.8%]) were based on low-very low-quality evidence (Table 1). Despite this, nearly half (7 [36.8%]) were characterised as strong recommendations (Tables 1 and 2).

4. Discussion

In the 2016 SSC guidelines, less than 10% of recommendations were supported by randomised controlled trials. Low, very-low quality evidence and expert opinion predominated in antimicrobial/source control, and nutrition recommendations. Our findings suggest that based on current evidence, defining a universally accepted standard of care is questionable. Patient-centred outcomes should be evaluated, optimally in clinical phase III trials with the relevant interventions, including complications, mortality and functional outcomes.

The Surviving Sepsis Guidelines have been adopted for use in emergency departments and intensive care units in many countries. Whilst some learning societies did not ratify the original version (e.g. ANZICS), the guidelines have been thoroughly endorsed and adopted in many institutions where all recommen-
The underlying 1-day variable recommendations are “standard of practice”. We have reported that although half of the recommendations were qualified as strong, a significant percentage of these were based on low-very low levels of evidence (see Fig. 2, Table 1). Nevertheless, we accept that the guidelines represent a crucial tool for the bedside caregiver. These controversies are one explanation of why SSC guidelines, as other guidelines, are not widely applied in our daily practice, with a variable compliance with clinical practice guidelines identified in a 1-day audit at 66 French adult intensive care units [10].

The observations of the current project lead the way to further attempts to upgrade these important guidelines. With the GRADE method, high-quality evidence is based on RCTs without major limitations; namely, on observational studies with large magnitude effects [4,11]. It should be acknowledged, however, although RCTs might be the most appropriate process, in sepsis, with heterogeneous pathogens, host responses and clinical presentations, conducting RCTs might be difficult, affecting overall quality of evidence. A study conducted on HAP and VAP guidelines also found that less than 10% of the recommendations were linked to high-quality evidence (based on RCTs), while the majority of the recommendations relied on expert opinion and case studies [5]. On the other hand, within the intensive care unit, critically ill patients often have altered physiological parameters that represent an important limitation for generalisation of conclusions from observational cohorts in non-critically ill patients. Individual recommendations personalised to patients with septic shock need to incorporate information from pharmacokinetic/pharmacodynamic studies, which have reported that underdosing is common in the ICU setting and validated in well-designed prospective studies [12,13]. Safety issues in the critically ill patient should be an additional concern [14,15].

At a practical level, our findings raise concerns on the empiric use of some recommendations and emphasise the need for reconsiderations and amendments when SSC guidelines will be updated in the future. An important recommendation that needs to be reappraised for example, is the volume of suggested fluid bolus (30 ml/kg) to be administered in septic patients with differing underlying conditions (e.g. abdominal sepsis versus pneumonia) [16] or those with alveolar-capillary damage (possibility of aggravating extravascular lung water) [16]. Another example is about lactate measurement in sepsis: measurement itself should be accompanied by a suggested intervention based on each measurement so as to improve patient management [17,18].

Whilst most of us would agree antibiotics are an important component of the treatment of sepsis, there is no mention to the heterogeneity of the syndromes [19,20]. Blanket use of antibiotics in all (or most) presentations of hypotension predisposes to the overuse of antibiotics with the concomitant side effects and downstream consequences of antibiotic administration, not the least of which is changes in the microbiome of patients [21]. The Infectious Diseases Society of America did not endorse SSC guidelines and expressed their concerns regarding recommendations for diagnosis and antimicrobial treatment in a public statement [22].

The goal of consensus guidance is to standardise care, improving outcomes limiting variability and dangerous practices, and defining standard of care to facilitate future research. This approach can not always be addressed by clinical trials, as in antimicrobial stewardship, infection control measures or diagnostic techniques. Recent data on poor evidence supporting antimicrobial stewardship in the ICU [23] reinforce the need to take in consideration the value of expert opinion. For instance, source control is fundamental for treatment, but it is not given high level of evidence in SSC guidelines. Observational studies in intra-abdominal infections are very consistent [24,25] on the role of source control and a randomised trial with no intervention would be unethical. However, studies using tools such as network meta-analyses [26] are needed to determine what delay in source control would be acceptable and what would drive the need for urgent surgical drainage.

Experts agree that a suggestion for an intervention should be used in the context of observational research while awaiting trial results; however, this does not replace randomised clinical trials for therapy. The risks of prescribing drugs or strategies not supported by clinical trials with comparative control groups has been addressed in a recent editorial comment regarding COVID-19 practices [27]. In presence of weak evidence to support strategies, different approaches can be developed as done by the American Thoracic Society Guidance for COVID-19 [28]. A pragmatic approach is the derivation of suggestions using a process that

Please cite this article in press as: Rello J, et al. Quality of evidence supporting Surviving Sepsis Campaign Recommendations. Anaesth Crit Care Pain Med (2020), https://doi.org/10.1016/j.accpm.2020.06.015
has been shown to create recommendations that are concordant with guideline recommendations created using Institute of Medicine adherent methodology [29,30]. Alternatively, a process of creating recommendations using multi-criteria decision analysis (MCDA) has been adopted for conflicting areas, such as management of ventilator-associated pneumonia or identification of a global priority pathogen list of multidrug resistant bacteria in the ICU [31–34].

Several limitations should be mentioned. First, the more recent guideline update included literature published until 2016. Since then, new evidence might have been published in controversial areas and evidence can be upgraded. Most CPGs are updated in periods longer than 5 years, with difficult incorporation of emerging evidence until next iteration. Published literature should be periodically reassessed to update CPGs references and recommendations, in the form of a dynamic document. Like in other guidelines, the creation of an adaptation framework for integration of new evidence in CPG [35] would avoid outdated recommendations and improve implementation in clinical practice. Second, we did not review literature supporting each recommendation and quality of evidence was not re-assessed. Analyses were based on the classification reported in the original report, with no changes in the rating assigned to the writing committee.

Despite these limitations, our study contains important strengths. It provides a detailed analysis of quality of evidence available in septic shock, remaining a meaningful assessment in evidence-based medicine. Indeed, areas in which higher quality evidence is scarce reveal research opportunities.

5. Conclusion

In conclusion, SSC recommendations were mainly supported by observational studies, case reports and expert opinion, implying controversial recommendations. To improve patient-centred outcomes further, well-designed, high-quality studies are required focusing on currently controversial areas. Guidelines based on stronger evidence will probably be more widely accepted and implemented to become a stronger tool that will complement the medical reasoning leading to improve patients’ outcomes. It is urgently needed to develop precision approaches based on high-quality clinical data. Adaptive multicentre trials with interim analysis can determine if an intervention is superior to another, modifying the standard of care quickly to test new therapies. Using multi-criteria decision analyses or a Delphi-like process, such as the Convergence of Opinion on recommendations and Evidence (CORE) process (using Institute of Medicine adherent methodology), are potential tools in making clinical recommendations in areas of weak evidence. This is particularly important because within the SSC guidelines most judgements were informed by indirect evidence and non-systematic observations. All suggestions need to be reconsidered as new evidence accumulates.

Disclosure of interest

JR served in the speaker’s bureau or consultant for Pfizer, MSD and Astellas. The other authors declare that they have no competing interest.

Funding

This work was supported in part by a grant from the Observationship Programme (EX) from the European Society of Clinical Microbiology & Infectious Diseases.

Compliance with ethical standards

Ethics committee approval was not required.

Author contributions

JR and JFC designed the study. The recommendations were abstracted by a single reviewer (EX) and validated by another reviewer (ST). CSL and LC revised the methodology. EX analysed the collected data. JR, ST, and EX wrote the first draft of the manuscript. DK and JL contributed scientifically in subsequent drafts. All authors approved the final version of the manuscript.

EX takes full responsibility for the integrity of reported data.

References

[1] Hotchkiss RS, Moldawer LL, Opal SM, Reinhardt K, Turnbull IR, Vincent JL. Sepsis and septic shock. Nat Rev Dis Primers 2016;2:16045. http://dx.doi.org/10.1038/nrdp.2016.45.
[2] World Health Organisation. Sepsis 2018, n.d. https://www.who.int/news-room fact-sheets/detail/sepsis (accessed December 17, 2019).
[3] Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Intensive Care Med 2017;43:304–77. http://dx.doi.org/10.1007/s00134-017-4683-6.
[4] Atkins D, Eccles M, Flottorp S, Guyatt GH, Henry D, Hill S, et al. Systems for grading the quality of evidence and the strength of recommendations: I: critical appraisal of existing approaches The GRADE Working Group. BMC Health Serv Res 2004;4:4–38. http://dx.doi.org/10.1186/1472-6963-4-38.
[5] Campogiani L, Tejada S, Ferreira-Coimbra J, Restrepo Mi, Rello J. Evidence supporting recommendations from international guidelines on treatment, diagnosis, and prevention of VAP in adults. Eur J Clin Microbiol Infect Dis 2020;39:483–91. http://dx.doi.org/10.1007/s10096-019-03748-z.
[6] Tejada S, Campogiani L, Ferreira-Coimbra J, Blot S, Rello J. Levels of evidence supporting clinical practice guidelines on invasive aspergillosis. Eur J Clin Microbiol Infect Dis 2020;39:903–13. http://dx.doi.org/10.1007/s10096-019-03794-7.
[7] Ferreira-Coimbra J, Tejada S, Campogiani L, Rello J. Levels of evidence supporting European and American community-acquired pneumonia guidelines. Eur J Clin Microbiol Infect Dis 2020;39:1158–67. http://dx.doi.org/10.1007/s10096-020-03833-8.
[8] Liberati A, Alfillen DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JPA, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 2009;62:e1–34. http://dx.doi.org/10.1016/j.jclinepi.2009.06.006.
[9] Jacobs AK, Kushner FG, Ettinger SM, Guyton RA, Anderson JL, Olman EM, et al. ACC/AHA clinical practice guideline methodology summit report: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013;61:213–65. http://dx.doi.org/10.1016/j.jacc.2012.09.025.
[10] Teboul JL, Ragnolet B, Flatter Ch, Allochonise B, Constantim J-M, Jabber S, et al. Variable compliance with clinical practice guidelines identified in a 1-day audit at 66 French adult intensive care units. Crit Care Med 2012;40:3189–95. http://dx.doi.org/10.1097/CCM.0b013e3182657512.
[11] Guyatt GH, Oxman AD, Kunz R, Vist GE, Falck-Ytter Y, Schunemann HJ, et al. What is “quality of evidence” and why is it important to clinicians? BMJ 2008;336:995–8. http://dx.doi.org/10.1136/bmj.39490.551108.BE.
[12] Blot S, Koulenti D, Akova M, Bassetti M, De Waerle J, Dimopoulos G, et al. Does continuing mandatory vancomycin dosing achieve therapeutic levels in heterogeneous clinical cohort of critically ill patients? Data from the multinational DALI study. Crit Care 2014;18:R99. http://dx.doi.org/10.1186/cc13874.
[13] Roberts JA, Paul SK, Akova M, Bassetti M, De Waerle J, Dimopoulos G, et al. Defining antibiotic levels in intensive care unit patients: are current β-lactam antibiotic doses sufficient for critically ill patients? Clin Infect Dis 2014;58:1072–83. http://dx.doi.org/10.1093/cid/ciu027.
[14] Roger C, Nucci B, Loaute B, Friggieri A, Khann I, Evrand A, et al. Impact of 30 mg/kg amikacin and 8 mg/kg gentamicin on serum concentrations in critically ill patients with severe sepsis. J Antimicrob Chemother 2016;71:208–12. http://dx.doi.org/10.1093/jac/dkv291.
[15] Loaute M, Roberts JA, Bassetti M, Bouglé A, Livine-P J, Legrand M, et al. Update in antibiotic therapy in intensive care unit: report from the 2019 Nimes International Symposium. Anaesth Crit Care Pain Med 2019;38:647–56. http://dx.doi.org/10.1016/j.accpm.2019.09.009.
[16] Hernández C, Cevalcarén AB, Osipina A, Ascan C, Zampieri FG, Dubin A, Hurtado FJ, et al. Early goal-directed therapy using a physiological holistic view: the Andromeda-Shock—a randomized controlled trial. Ann Intensive Care 2018;8:52. http://dx.doi.org/10.1186/s13613-018-0398-2.
[17] Hernández C, Osipina-Tascón GA, Damiani LP, Estenssoro E, Dubin A, Hurtado J, et al. Effect of a Resuscitation Strategy targeting peripheral perfusion status versus serum lactate levels on 28-day mortality among patients with septic shock: the Andromeda-Shock: a randomized Clinical trial. JAMA 2019;321:654–64. http://dx.doi.org/10.1001/jama.2019.0071.
[18] Zampieri FG, Damiani LP, Blakker J, Osipina-Tascón GA, Castro R, Cevalcarán AB, et al. Effects of a Resuscitation strategy targeting peripheral perfusion status versus serum lactate levels among patients with septic shock. A Bayesian random-effects analysis of the Andromeda-Shock Trial. Am J Respir Crit Care Med 2020;201:423–9. http://dx.doi.org/10.1164/rccm.201905-0968OC.
[19] Rhee C, Klovans M. New sepsis and septic shock definitions: clinical implications and controversies. Infect Dis Clin North Am 2017;31:397–413. http://dx.doi.org/10.1016/j.idc.2017.05.001.
[20] Stevens JP, Kachnizar B, Wright SB, Gillis J, Talmor D, Clardy P, et al. When policy gets it right: variability in US Hospitals’ diagnosis of ventilator-associated pneumonia. Crit Care Med 2014;42:497-503. http://dx.doi.org/10.1097/CCM.0b013e3182a66903.

[21] Armand-LeFevre L, Angebault C, Barbier F, Hamelet E, Defrance G, Ruppé E, et al. Emergence of imipenem-resistant gram-negative bacilli in intestinal flora of intensive care patients. Antimicrob Agents Chemother 2013;57:1488-95. http://dx.doi.org/10.1128/AAC.01823-12.

[22] IDSA Sepsis Task Force. Infectious Diseases Society of America (IDSA) POSITION STATEMENT: why IDSA did not endorse the Surviving Sepsis Campaign Guidelines. Clin Infect Dis 2018;66:1631-5. http://dx.doi.org/10.1093/cid/cix997.

[23] Tabah A, Bassetti M, Kollef MH, Zahir J-R, Paiva J-A, Timsit J-F, et al. Antimicrobial de-escalation in critically ill patients: a position statement from a task force of the European Society of Intensive Care Medicine (ESICM) and European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Critically Ill Patients Study Group (ESCICP). Intensive Care Med 2020;46:245-65. http://dx.doi.org/10.1007/s00134-019-05866-w.

[24] Lagués L, Rey-Pérez A, Martín-Gómez MT, Venà A, de Egea V, Muñoz P, et al. Association between source control and mortality in 258 patients with intra-abdominal candidiasis: a retrospective multi-center analysis comparing intensive care versus surgical wards in Spain. Eur J Clin Microbiol Infect Dis 2017;36:95-104. http://dx.doi.org/10.1007/s10096-016-2775-9.

[25] Bassetti M, Righi E, Ansaldi F, Merelli M, Trucchi C, Cecilia T, et al. A multicenter study of septic shock due to candidemia: outcomes and predictors of mortality. Intensive Care Med 2014;40:839-45. http://dx.doi.org/10.1007/s00134-014-3310-z.

[26] Remonti LR, Dias S, Lettão CB, Kramer CK, Klassman LP, Welton NJ, et al. Classes of anti-hypertensive agents and mortality in hypertensive patients with type 2 diabetes-Network meta-analysis of randomized trials. J Diabetes Complicat 2016;30:1192-200. http://dx.doi.org/10.1016/j.jdiacomp.2016.04.020.

[27] Waterer GW, Rello J, Wunderink RG. COVID-19: first do no harm. Am J Respir Crit Care Med 2020;201:1324-5. http://dx.doi.org/10.1164/rccm.202004-1153ED.

[28] Wilson KC, Chotirmall SH, Bai C. Rello J. COVID-19: Interim Guidance on Management Pending Empirical Evidence. From an American Thoracic Society-led International Task Force; 2020;12.

[29] Schoenberg NC, Barker AF, Bernardino J, Deterding RR, Essen JJ, Hess DR, et al. A comparative analysis of pulmonary and critical care medicine guideline development methodologies. Am J Respir Crit Care Med 2017;196:621–7. http://dx.doi.org/10.1164/rccm.201705-0926OC.

[30] Wilson KC, Schoenberg NC. Raghu G. Idiopathic Pulmonary Fibrosis Guideline Recommendations. Need for adherence to Institute of Medicine methodology? Annals ATS 2019;16:681–6. http://dx.doi.org/10.1513/AnnalsATS.201812-8710C.

[31] Rello J, Lode H, Cornaglia G, Masterton R. VAP Care Bundle Contributors. A European care bundle for prevention of ventilator-associated pneumonia. Intensive Care Med 2010;36:773-80. http://dx.doi.org/10.1007/s00134-010-1841-5.

[32] Rello J, Chastre J, Cornaglia G, Masterton R. A European care bundle for management of ventilator-associated pneumonia. J Crit Care 2011;26:3–10. http://dx.doi.org/10.1016/j.jcrc.2010.04.001.

[33] Ferreira-Coimbra J, Ardanuy C, Diaz E, Leone M, De Pascale G, Pivoa P, et al. Ventilator-associated pneumonia diagnosis: a prioritization exercise based on multi-criteria decision analysis. Eur J Clin Microbiol Infect Dis 2020;39:281–6. http://dx.doi.org/10.1007/s10096-019-03720-x.

[34] Rello J, Kalwaje Eshwara V, Lagunes I, Alves J, Wunderink RG, Conway-Morris A, et al. A global priority list of the Top Ten resistant Microorganisms (TOTEM) study at intensive care: a prioritization exercise based on multi-criteria decision analysis. Eur J Clin Microbiol Infect Dis 2019;38:319–23. http://dx.doi.org/10.1007/s10096-018-3428-y.

[35] Aliazzami W, Möller MH, Belley-Cote E, Citerio G. Intensive care medicine rapid practice guidelines (ICM-RPG): paving the road of the future. Intensive Care Med 2019;45:1639–41. http://dx.doi.org/10.1007/s00134-019-05786-9.